Therapeutic effects of modified Danggui Sini Decoction on plasma level of advanced glycation end products in patients with Wagner grade 0 diabetic foot: A randomized controlled trial

Journal of Chinese Integrative Medicine

Volumn 7, Issue 7, 2009, Pages 622-628

  You, Wei Hua ^a   Wang, Ping ^a   Li, Mao Qing ^a   Zhang, Yu ^a   Peng, Yu Lan ^b   Zhang, Feng Ling ^c  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^b CHANGSHA MEDICAL UNIVERSITY   (China)

^c the Third Affiliated Hospital of Guangxi Medical University: Nanning Second People's Hospital   (China)

Author keywords

Danggui sini decoction; Diabetic foot; Glycosylation end products; Randomized controlled trial; Wagner grade 0

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CILOSTAZOL; DANGGUI SINI DECOCTION; FIBRINOGEN; GLUCOSE; HEMOGLOBIN A1C; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG;

ACUPUNCTURE; ADULT; ANKLE BRACHIAL INDEX; ARTICLE; CHINESE MEDICINE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC FOOT; DIET RESTRICTION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOPPLER FLOWMETER; DRUG BLOOD LEVEL; DRUG SAFETY; ELECTROMYOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOSTASIS; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; NERVE CONDUCTION; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; THERAPY EFFECT; TRADITIONAL MEDICINE;

DIABETIC FOOT; DRUGS, CHINESE HERBAL; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; PHYTOTHERAPY;

EID: 73849101760     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jcim20090705     Document Type: Article

References (16)

1. Boulton AJ. The diabetic foot: a global view. Diabetes Metab Res Rev. 2000; 16(1): S2-S5.
2. Fryberg RG. Diabetic foot ulcerations: management and adjunctive therapy. Clin Podiatr Med Surg. 2003; 20(4): 709-728.
3. Zeng WH, Lai GM, Gan EH. Analysis of risk factors for diabetes foot amputation. Zhongguo Tang Niao Bing Za Zi. 2002; 10(4): 252-253. Chinese.
4. Jensen LJ, Stergaard J, Flyvbjerg A. AGE-RAGE and AGE cross-link interaction: important players in the pathogenesis of diabetic kidney disease. Horm Metab Res. 2005; 37(1): 26-34.
5. State Administration of Traditional Chinese Medicine. Diagnostic and therapeutic effect evaluation criteria of diseases and syndromes in traditional Chinese medicine. Nanjing: Nanjing University Press. 1994: 59-60. Chinese.
6. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complication, report of a WHO consultation. 1999: 1.
7. Li SM. Diagnosis and treatment of diabetic foot and its complication. Beging: People's Medical Publishing House. 2002: 168-169. Chinese.
8. Xue ZR. Classification of diabetic foot and progress of diagnosis and treatment. Nei Ke Ji Wei Zhong Zheng Za Zi. 2002; 8(1): 32-35. Chinese. Ê&&- 2002; 8(1): 32-35.
9. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 2004; 63(4): 582-592.
10. Enomoto M, Adachi H, Yamagishi S, Takeuchi M, Furuki K, Hino A, Hiratsuka A, Takajo Y, Imaizumi T. Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans. Metabolism. 2006; 55(7): 912-917.
11. Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SR, Cooper ME, Allen TJ. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes. 2004; 53(7): 1813-1823.
12. Basta G, Lazzerini G, Del Turco S, Ratto GM, Schmidt AM, De Caterina R. At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler Thromb Vasc Biol. 2005; 25(7): 1404-1407.
13. Frank GD, Eguchi S, Motley ED. The role of reactive oxygen species in insulin signaling in the vasculature. Antioxid Redox Signal. 2005; 7(7-8): 1053-1061.
14. Chang Z, Lu Y. Filtering the active ingredients of Chinese medicine with AGEs platform. Nanjing Zhong Yi Yao Da Xue Xue Bao. 2004; 20(3): 167-168. Chinese.
15. Xu HQ, Zhu Q, Li X, Zhang AH, Guo R. Inhibition of non-enzymic advanced glycation end products (AGEs) in vitro by seven TCMs. Zhong Cao Yao. 2002; 33(2): 145-147. Chinese with abstract in English.
16. Wang YJ, Wang XK, Chen LP. Effects of Danggui Sini Decoction and Lulutong Injection on treating diabetes leg arteriosclerosis obliterans. Zhongguo Zhong Yi Ji Chu Yi Xue Za Zi. 2004; 10(1): 60-62. Chinese with abstract in English.